Early antimicrobial prophylaxis in autologous stem cell transplant recipients: Conventional versus an absolute neutrophil count-driven approach

Justin G. Horowitz¹,² | Gerard W. Gawrys¹,² | Grace C. Lee²,³ | Brittney A. Ramirez¹,² | Carole M. Elledge⁴ | Paul J. Shaughnessy⁵

¹ Department of Pharmacy Services, Methodist Healthcare System, San Antonio, Texas, USA
² College of Pharmacy, The University of Texas at Austin, Austin, Texas, USA
³ Long School of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA
⁴ Adult Blood and Marrow Stem Cell Transplantation, Methodist Healthcare System, San Antonio, Texas, USA
⁵ Adult Blood and Marrow Stem Cell Transplantation, Texas Transplant Institute, San Antonio, Texas, USA

Correspondence
Justin Horowitz, Department of Pharmacy Services, Methodist Healthcare System, San Antonio, TX 78229, USA. Email: Justin.Horowitz@mhshealth.com

Abstract

Background: Autologous hematopoietic stem cell transplantation (HSCT) recipients are at increased risk of developing life-threatening infections. There is discordance in published recommendations for timing of pre- and post-transplant antimicrobial prophylaxis in this patient population, and these recommendations are unsubstantiated by any published comparative analyses.

Methods: An observational, pre- and post-intervention study of consecutive autologous HSCT recipients was conducted over a 2-year period. In the pre-intervention cohort, antimicrobial prophylaxis was initiated on the day prior to transplant. In the post-intervention cohort, antimicrobials were initiated once absolute neutrophil count (ANC) reached ≤500 cells/mm³. The primary outcome assessed was frequency of febrile occurrences. Secondary outcomes included total days of prophylaxis, positive blood cultures, all-cause mortality, Clostridioides difficile infection rates, and length of stay.

Results: A total of 208 patients were included in the final analysis, with 105 and 103 patients in the pre- and post-intervention cohorts, respectively. The majority of patients included were male. Lower rates of fever occurrences were observed in the post-intervention cohort (83% pre- vs. 69% post-intervention; p = 0.019). A significant reduction in the mean antibacterial days per patient was identified (9.7 vs. 4.6 days; p < 0.001). Other than lower rates of febrile neutropenia in the post-intervention cohort, no differences were identified in secondary outcomes. In multivariable analyses, ANC-driven prophylaxis was independently associated with decreased febrile events.

Conclusions: Delaying prophylaxis until severe neutropenia was not associated with increased febrile events or other secondary clinical outcomes evaluated. This approach is associated with a significant reduction in antimicrobial exposure.
1 | INTRODUCTION

Infections are a significant post-transplant complication in hematopoietic stem cell transplant (HSCT) recipients.1 Patients undergoing HSCT develop profound neutropenia following conditioning therapy and are at an increased risk for febrile neutropenia.2 Infectious bacterial complications occur in over 70% of transplant patients and are associated with significant morbidity and mortality.2,6 Antibacterial prophylaxis has proven to be beneficial in reducing rates of febrile neutropenia and infection throughout the duration of neutropenia and may reduce mortality.7-11 Additionally, randomized trials and large group analyses have supported antifungal prophylaxis with fluconazole demonstrating reduced invasive and superficial fungal infections, as well as candidiasis-related deaths.12-14

While the role of antimicrobial prophylaxis has been well-established, clinical data supporting the optimal timing for initiating these agents in HSCT patients are limited.15 The American Society of Blood and Marrow Transplantation guidelines recommend beginning antibacterial prophylaxis at the time of stem cell infusion.16 The American Society of Clinical Oncology (ASCO) guidelines recommend starting prophylactic antibacterial therapy during the period of neutropenia.17 Both guidelines are endorsed by the Infectious Diseases Society of America (IDSA).16,17 This discrepancy on timing of antimicrobial prophylaxis is of unique interest as neither guidance document cites literature to support this nuanced difference. Moreover, this discordance in recommendation is seen in clinical practice. A recent survey by the European Group for Blood and Marrow Transplantation identified that 57% of respondents began fluoroquinolone (FQ) prophylaxis at the onset of conditioning as compared to 32% at the time of stem cell infusion.18

Currently, literature is limited regarding optimal timing for initiation of antimicrobial prophylaxis in HSCT recipients. Patients are at greatest risk of infection when severely neutropenic which typically occurs several days following chemotherapy.19 Therefore, consistent with ASCO/IDSA recommendations, prophylaxis may be optimized if centered around the time of neutrophil nadir, rather than the time of stem cell infusion.

Alignment of antimicrobial prophylaxis initiation at the time of neutropenia may minimize unnecessary antimicrobial exposure. This difference in antimicrobial utilization can have profound benefits for HSCT patients and potentially influence antimicrobial resistance. Antimicrobial exposure is associated with an increased risk of multidrug resistant organisms. Clostridioides difficile (C. difficile) infections, drug-drug interactions, toxicities, and dysbiosis.20 Consequently, antimicrobial stewardship has implications for acute and long-term outcomes in HSCT recipients.

To the best of our knowledge, there have been no comparative studies evaluating the timing of antimicrobial prophylaxis initiation and outcomes in autologous HSCT patients. The aim of this study was to determine whether initiating antimicrobials at the time of neutropenia instead of prior to stem cell infusion in autologous HSCT patients is safe and efficacious.

2 | METHODS

2.1 | Study design and setting

A retrospective chart review was conducted of all consecutive adult HSCT recipients transplanted between November 2016 and November 2018 at a 900+ bed tertiary hospital. The Institutional Review Board approved this evaluation. The change in antimicrobial prophylaxis timing was initiated in November 2017. The pre-intervention cohort was defined as patients receiving antimicrobial prophylaxis beginning day –1 before stem cell infusion (day 0) between November 1, 2016 through October 31, 2017, and the post-intervention cohort was defined as patients who received absolute neutrophil count (ANC)-driven antimicrobial prophylaxis, defined as initiation upon ANC ≤ 500 cells/mm³, beginning December 1, 2017 through November 30, 2018.

2.2 | Patients

This investigation included patients admitted to an inpatient unit for autologous HSCT. Patients were excluded if they were less than 18 years of age at the time of transplant, received an allogeneic stem cell transplant, or had an ANC of ≤500 cells/mm³ prior stem cell infusion. Patients were also excluded if they had an active infection, fever, or received antibiotics prior to day –1 during hospital transplant admission. Lastly, patients were excluded if they deviated from the cohort’s antimicrobial initiation approach.

2.3 | Antimicrobial prophylaxis

Patients received levofloxacin 500 mg and fluconazole 400 mg daily adjusted for renal function. Cefdinir or micafungin was the alternative option if the patient was intolerant to levofloxacin and/or fluconazole, respectively. All patients continued anti-herpes therapy beginning on day –1. Antibacterial prophylaxis was discontinued upon neutrophil engraftment, defined as ANC ≥ 500 cells/mm³ following nadir, or with the development of a febrile episode in which the febrile neutropenia treatment protocol described below was initiated. Antifungal prophylaxis was discontinued upon neutrophil recovery. Patients received granulocyte colony stimulating factor (G-CSF), tbo-filgrastim, daily beginning on day +7 and continued until their was ANC ≥ 500 cells/mm³.
2.4 | Febrile neutropenia treatment protocol

At time of first fever, defined as 38.0°C (oral) or above, a standardized protocol was initiated which included escalation to an anti-pseudomonal beta-lactam (cefepime, piperacillin-tazobactam, or meropenem), collection of two sets of blood cultures, a urine culture, serum lactic acid and procalcitonin labs, a chest X-ray, intravenous fluids in the setting of hypotension, and discontinuation of oral antibacterial prophylaxis. Anti-pseudomonal beta-lactams were continued through neutrophil engraftment, completion of treatment for an identified infection, or antibiotics were de-escalated after neutrophil engraftment.

2.5 | Outcomes

The primary outcome evaluated was febrile events, defined by a fever occurrence of ≥38.0°C, beginning day −1 through discharge from HSCT admission. This interval was selected to account for engraftment syndrome-associated fevers. Secondary outcomes were evaluated from day −1 through discharge and included rates of febrile neutropenia, Clostridioides difficile infection rates, in-hospital all-cause-mortality, intensive care unit (ICU) admissions, bloodstream and invasive fungal infections, utilization of prophylaxis, and treatment with anti-pseudomonal beta-lactams. Length of stay was also evaluated as a secondary outcome and was defined as hospital admission from stem cell infusion, (day 0) through discharge.

A bloodstream infection event was defined as one or more positive blood cultures obtained during a febrile episode and determined to be a true pathogen versus contaminant by the transplant physician. Analyses further identified patients developing breakthrough infections resistant to the prophylactic agent, as these patients could theoretically develop bacteremia irrespective of timing of the antimicrobial prophylaxis. Antimicrobial susceptibilities were determined following Clinical and Laboratory Standards Institute standards and guidance.21

2.6 | Statistical analyses

The sample size calculation was based on the primary outcome of occurrence of febrile episodes. Previously published data suggest an outcome rate of 77% with prophylaxis with a fluoroquinolone.22 Using an effect size of 20%, a value of 0.05, it was determined a priori that a sample size of 98 patients was needed in each intervention group to achieve 80% power.

A chi-square or Fisher’s exact test was used to compare the primary outcome of febrile episodes and for other categorical data. Student’s t-tests were used for normally distributed continuous data, and Wilcoxon-rank sum tests were used for non-normally distributed continuous data. A multivariable logistic regression analysis for the primary outcome of occurrence of febrile episodes was conducted. Age, hematopoietic cell transplantation-specific comorbidity index (HCT-CI), intervention group, days of neutropenia, and variables in the univariate analyses with a p-value < 0.1 were entered into the model (Table S1).23 To assess association of intervention groups, hazard ratios (HRs) were calculated with 95% confidence intervals (CIs) using Cox-proportional hazards model and adjusted for HCT-CI, conditioning regimen, and days of neutropenia. SPSS 24.0 (IBM Corp, Armonk, NY, USA) was used for all statistical analyses. Statistical significance was calculated using a p-value of < 0.05.

3 | RESULTS

Of the 351 transplanted patients, a total of 208 patients were included in the final analysis (Figure 1). One hundred ten patients were excluded as they had undergone allogeneic HSCT, and 33 additional patients were excluded due to deviation from intervention period protocol or incomplete data.

Of the 208 autologous transplant recipients, 105 were in the pre-intervention cohort and 103 in the post-intervention cohort. The majority of patients were male (61%) with a mean age of 54 years. The primary indication for transplant was plasma cell disorders, followed by non-Hodgkin lymphoma. No statistically significant differences were identified in baseline characteristics between cohorts (Table 1).

A significant difference was observed in rates of febrile episodes between the pre- and post-intervention cohorts (83% vs. 69%, respectively; p = 0.019). Three patients in both the pre- and post-intervention cohorts developed fever prior to neutropenia (2.8% vs. 2.9%). Additionally, rates of febrile neutropenia were also higher in the pre-intervention group (p = 0.032; Table 2). Characteristics of those with febrile episodes and no febrile episodes are described in Table S1. In multivariable analysis, treatment during the pre-intervention period was independently associated with febrile events (aOR 2.71, 95% CI, 1.36–5.59; Table 3).

Time to first febrile event was shorter in the post-intervention than pre-intervention cohort. However, the intervention group was not a significant predictor in the Cox-proportional hazard model (Figure 2). Duration of G-CSF use from stem cell infusion did not show a statistically significant difference between cohort groups.

Regarding secondary outcomes, rates of bloodstream infections did not differ between groups (pre-intervention 8.6% vs. 14.5% post-intervention; p = 0.493). No patients in either group developed invasive fungal infection. Only one patient developed E. coli bacteremia prior to initiation of prophylaxis, which occurred in the post-intervention cohort. Moreover, the rates of ICU admissions, hospital length of stay, or in-hospital all-cause mortality also did not differ (Table 2). Three deaths occurred during the hospital admission; in the pre-intervention cohort, one patient died of cardiac arrhythmia and the other due to pan-resistant Pseudomonas bacteremia. One patient in the post-intervention cohort died of influenza A pneumonia.

3.1 | Antimicrobial utilization

The utilization of antimicrobials, both prophylactic and treatment, was evaluated between the pre- and post-intervention cohorts (Table S2). Across all transplant patients evaluated, significant differences were
FIGURE 1  Flow chart of study population

TABLE 1  HSCT patient characteristics

| Variable                              | Pre-intervention n = 105 | Post-intervention n = 103 | p-Value<sup>ab</sup> |
|---------------------------------------|--------------------------|---------------------------|----------------------|
| Age; median (IQR)                     | 58 (17)                  | 56 (25)                   | 0.430                |
| Sex, male; n (%)                      | 60 (57)                  | 67 (65)                   | 0.242                |
| White race; n (%)                     | 95 (90)                  | 95 (92)                   | 0.384                |
| HCT-CI; median (IQR)                  | 2 (3)                    | 3 (4)                     | 0.397                |
| Pre-transplant diagnosis; n (%)       |                          |                           |                      |
| Hodgkin lymphoma                      | 15 (14)                  | 12 (12)                   | 0.572                |
| Non-Hodgkin lymphoma                  | 25 (24)                  | 28 (27)                   | 0.577                |
| Germ cell tumor                       | 3 (3)                    | 7 (7)                     | 0.212                |
| Plasma cell disorders                 | 62 (59)                  | 56 (54)                   | 0.496                |
| Conditioning regimen; n (%)           |                          |                           |                      |
| Myeloablative                         | 100 (95)                 | 101 (98)                  | 0.259                |
| Reduced-intensity/Non-myeloablative   | 5 (5)                    | 2 (2)                     | 0.445                |
| History of multi-drug resistant organism; n (%) | 2 (2)     | 0                         | 0.498                |
| Days of ANC ≤ 500; median (IQR)       | 7 (2)                    | 7 (2)                     | 0.194                |
| Number of GCSF doses per patient; median (IQR) | 5 (1) | 4 (1) | 0.140          |

Abbreviations: ANC, absolute neutrophil count; GCSF, granulocyte-colony stimulating factor; HCT-CI, hematopoietic cell transplantation-specific comorbidity index.<sup>23</sup>

<sup>a</sup>n (%) calculated using Fisher’s exact test.

<sup>b</sup>Medians, interquartile range (IQR) (displayed as difference between Q3 and Q1); calculated using Wilcoxon rank sum.

seen in utilization of prophylactic antibacterials and antifungals (Figure 3). Total antibacterial prophylactic days of therapy were 1021 and 439 in the pre- and post-intervention cohorts, respectively. This accounted for a difference of 9.7 versus 4.6 days of antibiotic prophylaxis per patient (p < 0.001). Antifungal prophylactic days of therapy also differed with a total of 1303 versus 679 antifungal days, which was associated with 12.4 versus 6.6 days per patient when comparing cohorts (p < 0.001). Total anti-pseudomonal beta-lactam days of therapy did not differ significantly with 521 and 461 days of therapy in the respective pre- and post-intervention groups, which was
TABLE 2  HSCT clinical outcomes

| Outcome                                           | Pre-intervention | Post-intervention | p-Value\textsuperscript{a,\textsuperscript{b}} |
|---------------------------------------------------|------------------|-------------------|-----------------------------------------------|
| Febrile event; n (%)                              | 87 (83)          | 71 (69)           | 0.019                                         |
| Fever and ANC ≤ 500; n (%)                        | 85 (81)          | 70 (68)           | 0.032                                         |
| Interval between transplant and fever; median (IQR)| 7 (4)            | 6 (4)             | 0.034                                         |
| C. difficile infection; n (%)                     | 5 (4.8)          | 10 (9.7)          | 0.168                                         |
| In-hospital-all-cause mortality; n (%)            | 2 (2)            | 1 (1)             | 0.572\textsuperscript{a}                      |
| Length of stay; median (IQR)                      | 16 (3)           | 16 (4)            | 0.760                                         |
| ICU admission; n (%)                              | 4 (4)            | 7 (7)             | 0.371\textsuperscript{a}                      |
| Bloodstream infection, n (%)	extsuperscript{c,d} | 9 (8.6)          | 15 (14.5)         | 0.493                                         |
| Number of positive cultures per person; median (IQR)| 2 (1)           | 1 (1)             | 0.300                                         |
| Bloodstream infection with FQ-resistant organism, n (%)	extsuperscript{d} | 4 (3.8)          | 6 (5.8)           | 0.277                                         |
| Bloodstream infection with ceftriaxone-resistant organism, n (%)\textsuperscript{d} | 0                | 2 (1.9)           | 0.349                                         |

Abbreviations: ANC, absolute neutrophil count; C. difficile, Clostridioides difficile; FQ, fluoroquinolone; ICU, intensive care unit.

\textsuperscript{a}n (%) calculated using Fisher’s exact test.
\textsuperscript{b}Medians, interquartile range (IQR) (displayed as difference between Q3 and Q1); calculated using Wilcoxon rank sum.
\textsuperscript{c}No fungal organisms were identified. Pathogens identified by blood culture can be found in Table S3.
\textsuperscript{d}Susceptibility testing was conducted according to institutional clinical microbiological protocols.

TABLE 3  Multivariable analysis for febrile events

|                          | Adjusted odds ratio (95% Confidence Interval)\textsuperscript{a} | p-Value\textsuperscript{a} |
|--------------------------|------------------------------------------------------------------|-----------------------------|
| Pre-intervention\textsuperscript{b} | 2.71 (1.36–5.59)                                                 | 0.005                       |
| HCT-CI                   | 1.00 (0.84–1.20)                                                  | 0.999                       |
| Non-Hodgkin lymphoma\textsuperscript{c} | 4.81 (1.03–22.47)                                               | 0.046                       |
| Plasma cell disorders\textsuperscript{c} | 0.73 (0.22–2.47)                                                 | 0.611                       |
| Days of neutropenia\textsuperscript{d} | 1.00 (0.97–1.04)                                                 | 0.819                       |
| Age                      | 0.97 (0.94–1.01)                                                  | 0.101                       |

Abbreviation: HCT CI, hematopoietic cell transplantation-specific comorbidity index.\textsuperscript{23}

\textsuperscript{a}Calculated using logistic regression.
\textsuperscript{b}Reference: Post-intervention.
\textsuperscript{c}Reference: Hodgkin lymphoma.
\textsuperscript{d}Odds ratio for 1-day increase.

FIGURE 2  Febrile events over time in HSCT recipients who fevered

Disproportionate fever associated with a non-statistically significant difference in therapy days per patient (5.0 vs. 4.5 days; p = 0.365).

4 DISCUSSION

This study was the first of its kind to evaluate timing of prophylactic antimicrobial initiation in autologous HSCT recipients. Our data support an ANC-driven approach to antimicrobial initiation and discontinuation, which appears to be safe and at least equally effective in preventing febrile events in this at-risk population.

A large reduction in antimicrobial utilization was demonstrated using the ANC-driven approach. Roughly 5 days of both prophylactic antibacterial and antifungal therapy per patient were saved, accounting for a significant overall reduction in total days of antimicrobial exposure. This practice is associated with a relatively higher reduction in antimicrobial utilization compared to other stewardship approaches.\textsuperscript{24–27}

Interestingly, we saw fewer events of neutropenic fever when antimicrobial prophylaxis was delayed until neutropenia; these rates are consistent with what has previously been reported in the literature.\textsuperscript{28} This finding was further validated in the multivariable analysis. Although the direct cause for reduced febrile events cannot be fully explained, this finding supports the safety of reducing antimicrobials. To our knowledge, there is sparse literature to suggest drug-induced fever caused by levofloxacin and/or fluconazole. Furthermore, these rates of FN are consistent with previously reported rates in the literature.\textsuperscript{2}

An appreciable difference in anti-pseudomonal beta-lactam use between the pre- and post-implementation was not seen. Given that the use of these broad-spectrum agents serves as a surrogate for fever
and infection, this finding reinforces the safety and efficacy of this novel approach to prophylaxis.

Although the use of prophylactic antibacterial therapies has been shown to decrease gram-negative bacteremia, infection-related outcomes, and mortality, overutilization and unwarranted use of antimicrobials can be associated with adverse events in HSCT recipients. 7–11 The well-established toxicities of FQs should be appreciated, along with the decreased susceptibilities of gram-negative pathogens to this drug class.28 Our study showed a 53% reduction in combined antibacterial and antifungal therapies without adversely impacting clinical outcomes.

With the incorporation of nearly universal FQ prophylaxis in HSCT patients, resistance continues to be a major concern.29 Overexposure to FQs does not only lead to FQ resistance, but it has been shown that FQ prophylaxis was an independent predictor for bacteremia with breakthrough meropenem-non-susceptible Pseudomonas aeruginosa isolates in this patient population.30

This study did not show a difference in rates of Clostridiodes difficile. Of note, testing methodology at our facility did not change during the period of this analysis. Given antibiotic exposure is not the only risk factor for Clostridiodes difficile in HSCT patients, the abundance of data surrounding the reduction of FQ use and the impact on Clostridiodes difficile rates in other larger scale studies must be acknowledged.31 These rates of Clostridiodes difficile are consistent with previously reported literature, but we hypothesize that larger sample sizes may have showed an appreciable difference in Clostridiodes difficile infections.32,33

This study is not without limitations as it is a single center, retrospective, non-randomized, and unblinded investigation. As with pre- and post-intervention analyses, undetected confounding factors impacting outcomes could have been introduced. Because interpretation of cultures from non-sterile sites (i.e., sputum, urine, skin) can be variable, our definition of infection only included positive blood cultures. It is possible that other microbiologically significant infections were not identified with this focus, although our primary outcome of fever may have captured these patients. Our analysis serves as a foundation to a better understanding of where antimicrobial stewardship in HSCT impacts patient outcomes and may stimulate further investigations, including in the allogeneic HSCT population where the intricate synergism of the gut microbiota and risk for graft-versus-host disease is of particular interest.34–36
5 | CONCLUSION

Utilizing an ANC-driven approach to guide antimicrobial prophylaxis initiation appears to be feasible and safe in this highly immunocompromised population. This approach is associated with a reduction in antimicrobial exposure. These results support ASCO guideline recommendations for initiation of antimicrobials upon neutropenia and suggest opportunity in reducing unnecessary antimicrobial exposure, which may have numerous deleterious downstream effects in HSCT patients.

ACKNOWLEDGMENTS

The authors would like to thank Drs. Amy Morrow and Nina Hull for research and manuscript review.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

AUTHOR CONTRIBUTIONS

Concept design: Justin G. Horowitz, Gerard W. Gawrys, Grace C. Lee, Brittney A. Ramirez, Carole M. Elledge, and Paul J. Shaughnessy. Data collection: Justin G. Horowitz, Gerard W. Gawrys, and Brittney A. Ramirez. Data analysis: Justin G. Horowitz, Gerard W. Gawrys, Grace C. Lee, Brittney A. Ramirez, and Paul J. Shaughnessy. Data interpretation: Justin G. Horowitz and Gerard W. Gawrys. Manuscript drafting: Justin G. Horowitz, Gerard W. Gawrys, Grace C. Lee, Brittney A. Ramirez, and Carole M. Elledge. Revisions and manuscript approval: Justin G. Horowitz, Gerard W. Gawrys, Grace C. Lee, Carole M. Elledge, Paul J. Shaughnessy, and Brittney A. Ramirez. Statistical analysis: Grace C. Lee.

ORCID

Justin G. Horowitz https://orcid.org/0000-0003-2292-5525
Gerard W. Gawrys https://orcid.org/0000-0002-8935-7529
Grace C. Lee https://orcid.org/0000-0002-7653-3028
Brittney A. Ramirez https://orcid.org/0000-0003-0639-4795
Carole M. Elledge https://orcid.org/0000-0003-1982-6614
Paul J. Shaughnessy https://orcid.org/0000-0003-4023-3864

REFERENCES

1. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52(4):e56–e93.
2. Çelebi H, Akan H, Akçağlayan E, Üstün C, Arat M. Febrile neutropenia in allogeneic and autologous peripheral blood stem cell transplantation and conventional chemotherapy for malignancies. Bone Marrow Transplant. 2000;26(2):211–214.
3. Frère P, Hermanne J-P, Debouge M-H, De Mol P, Fillet G, Béguin Y. Bacteremia after hematopoietic stem cell transplantation: incidence and predictive value of surveillance cultures. Bone Marrow Transplant. 2004;33(7):745–749.
4. Frère P, Baron F, Bonnet C, et al. Infections after allogeneic hematopoietic stem cell transplantation with a nonmyeloablative conditioning regimen. Bone Marrow Transplant. 2006;37(4):411–418.
5. Dandoy CE, Ardura MI, Papanicolau GA, Auletta JJ. Bacterial bloodstream infections in the allogeneic hematopoietic cell transplant patient: new considerations for a persistent nemesis. Bone Marrow Transplant. 2017;52(8):1091–1106.
6. Gudiol C, García-Vidal C, Arnan M, et al. Etiology, clinical features and outcomes of pre-engraftment and post-engraftment bloodstream infection in hematopoietic SCT recipients. Bone Marrow Transplant. 2014;49(6):824–830.
7. Bucaneve G, Micozzi A, Menichetti F, et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med. 2005;353(10):977–987.
8. Reuter S, Kern WV, Sigge A, et al. Impact of fluoroquinolone prophylaxis on reduced infection-related mortality among patients with neutropenia and hematologic malignancies. Clin Infect Dis. 2005;40(8):1087–1093.
9. Cruciani M, Rampazzo R, Malena M, et al. Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a meta-analysis. Clin Infect Dis. 1996;23(4):795–805.
10. Engels EA, Lau J, Barza M. Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. J Clin Oncol. 1998;16(3):1179–1187.
11. Gafter-Gvili A, Fraser A, Paul M, van de Wetering M, Kremer L, Leibovici L. Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane Database Syst Rev. 2012;1:CD004386.
12. Rotstein C, Bow EJ, Laverdiere M, Ioannou S, Carr D, Moghaddam N. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group. Clin Infect Dis. 1999;28(2):331–340.
13. Robenshtok E, Gafter-Gvili A, Goldberg E, et al. Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem cell transplantation: systematic review and meta-analysis. J Clin Oncol. 2007;25(34):5471–5489.
14. Wirk B, Wingard JR. Current approaches in antifungal prophylaxis in high risk hematologic malignancy and hematopoietic stem cell transplant patients. Mycopathology. 2009;168(6):299–311.
15. Averbuch D, Orasch C, Cordonnier C, et al. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia. Haematologica. 2013;98(12):1826–1835.
16. Tymblon M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009;15(10):1143–1238.
17. Taplitz RA. Kennedy EB, Bow EJ, et al. Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA Clinical Practice Guideline Update. J Clin Oncol. 2018;36(30):3043–3054.
18. Verlinden A, Mikułska M, Knelange NS, Averbuch D, Styczynski J. Infectious Diseases Working Party (IDWP) of the European Group for Blood and Marrow Transplantation Group (EBMT). Current antimicrobial practice in febrile neutropenia across europe and asia: the ebmt infectious disease working party survey. Bone Marrow Transplant. 2020;55(8):1588–1594.
19. Li Y, Klippel Z, Shih X, Reiner M, Wang H, Page JH. Relationship between severity and duration of chemotherapy-induced neutropenia and risk of infection among patients with nonmyeloid malignancies. Support Care Cancer. 2016;24(10):4377–4383.
20. Horton LE, Haste NM, Taplitz RA. Rethinking antimicrobial prophylaxis in the transplant patient in the world of emerging resistant organisms—where are we today?. Curr Hematol Malig Rep. 2018;13(1):59–67.
21. CLSI. Performance standards for Antimicrobial Susceptibility Testing. 29th ed. Clinical and Laboratory Standards Institute; 2019.
22. Modi D, Jang H, Kim S, et al. Fluoroquinolone prophylaxis in autolo-
gous hematopoietic stem cell transplant recipients. Support Care Can-
cer. 2017;25(8):2593–2601.
23. Sorror ML, Storb RF, Sandmaier BM, et al. Comorbidity-age index: a
clinical measure of biologic age before allogeneic hematopoietic cell
transplantation. J Clin Oncol. 2014;32(29):3249–3256.
24. Seo SK, Lo K, Abbo LM. Current state of antimicrobial stewardship at
solid organ and hematopoietic cell transplant centers in the United
States. Infect Control Hosp Epidemiol. 2016;37(10):1195–1200.
25. Robilotti E, Holubar M, Seo SK, Deresinski S. Feasibility and applicabil-
ity of antimicrobial stewardship in immunocompromised patients. Curr
Opin Infect Dis. 2017;30(4):346–353.
26. Sexton ME, Langston AA, Wiley Z, Nowak MD, Jacob JT. Antimicrobial
stewardship in the hematopoietic stem cell transplant population. Curr
Treat Options Infect Dis. 2018;10:249–262.
27. Pillinger KE, Bouchard J, Withers ST, et al. Inpatient antibiotic stew-
dardship interventions in the adult oncology and hematopoietic stem
cell transplant population: a review of the literature. Ann Pharmacother.
2020;54(6):594–610.
28. Wong-Beringer A, Nguyen LH, Lee M, Shriner KA, Pallares J. An anti-
microbial stewardship program with a focus on reducing fluoroquinolone
overuse. Pharmacotherapy. 2009;29(6):736–743.
29. Mikulska M, Del Bono V, Raiola AM, et al. Blood stream infections in
allogeneic hematopoietic stem cell transplant recipients: reemergence
of Gram-negative rods and increasing antibiotic resistance. Biol Blood
Marrow Transplant. 2009;15(1):47–53.
30. Hakki M, Humphries RM, Hemarajata P, et al. Fluoroquinolone pro-
phylaxis selects for meropenem-nonsusceptible pseudomonas aerugi-
nosa in patients with hematologic malignancies and hematopoietic cell
transplant recipients. Clin Infect Dis. 2019;68(12):2045–2052.
31. Dingle KE, Didelot X, Quan TP, et al. Effects of control interventions
on Clostridiodes difficile infection in England: an observational study.
Lancet Infect Dis. 2017;17(4):411–421.
32. Alonso CD, Marr KA. Clostridioides difficile infection among
hematopoietic stem cell transplant recipients: beyond colitis. Curr
Opin Infect Dis. 2013;26(4):326–331.
33. Alonso CD, Treadway SB, Hanna DB, et al. Epidemiology and outcomes
of Clostridioides difficile infections in hematopoietic stem cell trans-
plant recipients. Clin Infect Dis. 2012;54(8):1053–1063.
34. Staffas A, Burgos Da Silva M, Van Den Brink MR. The intesti-
nal microbiota in allogeneic hematopoietic cell transplant and graft-
versus-host disease. Blood. 2017;129(8):927–933.
35. Holler E, Butzhammer P, Schmid K, et al. Metagenomic analysis of the
stool microbiome in patients receiving allogeneic stem cell transplanta-
tion: loss of diversity is associated with use of systemic antibiotics
and more pronounced in gastrointestinal graft-versus-host disease. Biol Blood Marrow Transplant. 2014;20(5):640–645.
36. Beelen DW, Elmaagaci A, Müller KD, Hirche H, Schaefer UW. Influence
of intestinal bacterial decontamination using metronidazole and
ciprofloxacin or ciprofloxacin alone on the development of acute graft-
versus-host disease after marrow transplantation in patients with
hematologic malignancies: final results and long-term follow-up of an
open-label prospective randomized trial. Blood. 1999;93(10):3267–3275.

SUPPORTING INFORMATION
Additional supporting information may be found online in the Support-
ing Information section at the end of the article.

How to cite this article: Horowitz JG, Gawrys GW, Lee GC, Ramirez BA, Elledge CM, Shaughnessy PJ. Early antimicrobial
prophylaxis in autologous stem cell transplant recipients: Conventional versus an absolute neutrophil count-driven
approach. Transpl Infect Dis. 2021;23:e13689.
https://doi.org/10.1111/tid.13689